<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150106020588N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-13</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of Atropine and Tetracaine on  Oculo Cardiac Reflex (OCR) in strabismus surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of preoperative administration of intravenous Atropine and topical Tetracaine on the incidence and severity of Oculo Cardiac Reflex (OCR) in strabismus surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64654</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: This is a simple randomized clinical trial in which patients entered the study groups by lottery; The medicines and placebo were placed in sealed, opaque, and similar form packets which were coded. Each code was also written on a piece of paper, folded, and placed inside a box. After entering the operating 
room, each patient took one of the papers out of the box; The pocket with the same number was the intervention that was applied to him. This process continued till the number of patients reached the desired one, Blinding description: This is a triple-blind clinical trial; In this way, before obtaining consent, patients were informed about the study but didn't know which group they would be in and therefore were blind. Also, the researcher who recorded the patient's symptoms was different from the nurse who injected the drug and didn't know the type of drug and was blind. Analysts who analyzed the data collected during the study also didn't know the type of intervention applied in each group and were blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Strabismus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, they received 0.5 mg of Atropine manufactured by Caspian Pharmaceutical Company intravenously, as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery. Intervention 2: Intervention group 2: Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, They received 3 to 5 drops of 0.5% topical Tetracaine made by Sinadaro in 4 directions on the eyeball. as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery. Intervention 3: Control group : Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, They received 3 to 5 drops of Artificial tears made by Sinadaro in 4 directions on the eyeball. as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dariush Moradi Farsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 8597</telephone>
        <email>dmoradi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dariush Moradi Farsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 8597</telephone>
        <email>dmoradi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate for Strabismus surgery
Age 10 to 70 years
ASA class I and II
informed consent to enter the study</inclusion_criteria>
      <agemin>10 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergic to Atropine, Tetracaine and artificial tears
Cardiovascular diseases history</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other strabismus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, they received 0.5 mg of Atropine manufactured by Caspian Pharmaceutical Company intravenously, as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery.</i_keyword>
      <i_keyword>Intervention group 2: Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, They received 3 to 5 drops of 0.5% topical Tetracaine made by Sinadaro in 4 directions on the eyeball. as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery.</i_keyword>
      <i_keyword>Control group : Patients in this group after inducting of anesthesia using 5 mg/kg of Thiopental sodium manufactured by Elixir Company, an amount of 0.5 mg/kg of Atracurium manufactured by Caspian Pharmaceutical Company, and the amount of 2 M/kg of Fentanyl manufactured by Aburihan Company, after preparing the eyes and allowing access to the operation site by the surgeon, They received 3 to 5 drops of Artificial tears made by Sinadaro in 4 directions on the eyeball. as well as maintenance of anesthesia using Propofol 100 mg/kg/min was administered. the patient's symptoms were measured and recorded until the end of the operation and then during recovery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart Rate. Timepoint: Before induction, immediately after the induction of anesthesia and then every 5 minutes to 30 minutes, and then every 10 minutes until the end of the surgery. Method of measurement: ECG monitoring.</prim_outcome>
      <prim_outcome>Blood Pressure. Timepoint: Before induction, immediately after the induction of anesthesia and then every 5 minutes to 30 minutes, and then every 10 minutes until the end of the surgery. Method of measurement: Sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Surgery Duration. Timepoint: From the moment of surgical intervention to the end of eye dressing. Method of measurement: Timer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-11</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
